Did Exact Sciences Corp. (EXAS) perform well in the last session?

While Exact Sciences Corp. has underperformed by -2.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EXAS fell by -5.31%, with highs and lows ranging from $100.77 to $58.43, whereas the simple moving average fell by -15.17% in the last 200 days.

On January 02, 2024, The Benchmark Company Upgraded Exact Sciences Corp. (NASDAQ: EXAS) to Buy.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Analysis of Exact Sciences Corp. (EXAS)

Further, the quarter-over-quarter increase in sales is 20.12%, showing a positive trend in the upcoming months.

In order to gain a clear picture of Exact Sciences Corp.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -9.06% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.13, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

An average volume of 1.67M can be a very valuable indicator of volatility for EXAS stock. On a monthly basis, the volatility of the stock is set at 3.71%, whereas on a weekly basis, it is put at 3.71%, with a gain of 0.23% over the past seven days. Furthermore, long-term investors anticipate a median target price of $91.55, showing growth from the present price of $64.22, which can serve as yet another indication of whether EXAS is worth investing in or should be passed over.

How Do You Analyze Exact Sciences Corp. Shares?

In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.94%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 92.24% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

Are institutional investors increasing their holdings in EXAS shares?

The recent increase in stakes in EXAS appears to be a result of several institutional investors and hedge funds increasing their positions. The Vanguard Group, Inc.’s position in EXAS has decreased by -0.69% in the first quarter. The company now owns 17,056,321 shares of the stock, with a value of $1.26 billion, following the sale of -118,410 additional shares during the last quarter. JPMorgan Investment Management, I made another increased to its shares in EXAS during the first quarter, upping its stake by 24.60%. During the last quarter, the company picked up 3,027,695 additional shares for a total stake of worth $1.13 billion, bringing number of shares owned by the company to 15,334,706.

During the first quarter, Wellington Management Co. LLP added a 17,511 position in EXAS. BlackRock Fund Advisors purchased an additional 0.17 million shares in the last quarter, increasing its holdings by 2.22%, now holding 7.7 million shares worth $569.72 million. At the end of the first quarter, Capital Research & Management Co increased its EXAS holdings by 1.92% and now holds 6.93 million EXAS shares valued at $512.58 million with the added 0.13 million shares during the period. EXAS shares are owned by institutional investors to the tune of 92.24% at present.

Related Posts